1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
    Meeting Abstract

    van Cutsem, E.; Di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J. A.; Chao, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
    Meeting Abstract

    Weiss, J.; Yaeger, R. D.; Johnson, M. L.; Spira, A.; Klempner, S. J.; Barve, M. A.; Christensen, J. G.; Chi, A.; Der-Torossian, H.; Velastegui, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
    Meeting Abstract

    Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla Mercade, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer
    Meeting Abstract

    Arnold, D.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla Mercade, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
    Meeting Abstract

    Catenacci, D. V.; Strickler, J. H.; Shitara, K.; Nakamura, Y.; Janjigian, Y. Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H. J.; Chung, H. C.; Tabernero, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Ku, G.; Elimova, E.; Denlinger, C. S.; Mehta, R.; Lee, K. W.; Iqbal, S.; Kang, Y. K.; Oh, D. Y.; Rha, S. Y.; Kim, Y. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Genomic landscape of late-stage gastric cancer
    Meeting Abstract

    Janjigian, Y. Y.; Cecchini, M.; Shitara, K.; Enzinger, P. C.; Wainberg, Z. A.; Catenacci, D. V.; Chau, I.; Satoh, T.; Lee, J.; Loboda, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • EGFR inhibition in EGFR-amplified esophagogastric cancer (EGC): Retrospective global experience
    Meeting Abstract

    Maron, S.; Moya, S.; Morano, F.; Emmett, M. J.; Disel, U.; Chalasani, S.; Ku, G.; Kasi, P. M.; Uboha, N.; Kato, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study
    Meeting Abstract

    Baudin, E.; Horsch, D.; Singh, S.; Caplin, M. E.; Ferone, D.; Wolin, E. M.; Capdevila, J.; Buikhuisen, W. A.; Raderer, M.; Dansin, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results
    Meeting Abstract

    Naing, A.; Rosen, L.; Camidge, R. D.; Khalil, D.; Davies, J.; Miles, D.; Patel, M.; Cockle, P.; Champion, B.; Krige, D.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save